Document is current
Any future updates will be listed below
-
Authors
Pradenas, Edwards https://orcid.org/0000-0001-5162-8920
Urrea, Victor
Marfil, Silvia
Pidkova, Tetyana
Aguilar-Gurrieri, Carmen
Abancó, Ferran
Mateu, Lourdes
Chamorro, Anna
Grau, Eulàlia
Trigueros, Macedonia
Carrillo, Jorge
Massanella, Marta
Trinité, Benjamin
Clotet, Bonaventura
Blanco, Julià
-
Funding
Funding for this research was provided by:
Grifols
Departament de Salut, Generalitat de Catalunya (DSL016, 2021 SGR 00452)
Instituto de Salud Carlos III (PI23/01269, PI20/00093)
- License Information
-
More Information
Article History
Received: 7 March 2025
Accepted: 5 July 2025
First Online: 11 July 2025
Declarations
:
: The studies were approved by the Hospital Ethics Committee Board from Hospital Universitari Germans Trias i Pujol (HUGTiP: PI-20-122, PI-20-217 and PI-21-351 for KING, KING cohort extension and KING-VAX cohorts, respectively). All participants provided written informed consent.
: Not applicable.
: J.B. declares institutional grants from HIPRA, NESAPOR EUROPE and MSD, and personal consultancy fees from NESAPOR EUROPE and HIPRA. Unrelated to the submitted work, J.B. and J.C. were founders and shareholders of AlbaJuna Therapeutics. SL. B.C. was founder and shareholder of AlbaJuna Therapeutics SL. and AELIX Therapeutics. SL. The other authors declare no competing interests.
